Tirzepatide (GLP-1/GIP): 10mg
Weight managementDescription
Glp-1 dual agonist peptides target both the glp-1 receptor and the gip (glucose-dependent insulinotropic polypeptide) receptor simultaneously. glp-1 and gip receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. the dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single glp-1 agonism alone. phase 3 clinical trials with dual gip/glp-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. gastrointestinal side effects are typically milder than with glp-1 mono-agonists due to the complementary gip receptor mechanism. for research and educational purposes only. not fda-approved for all formulations. consult a qualified healthcare professional.
Specifications
| Amount in Vial | 10mg |
|---|---|
| BAC Water | 1ml |
| Amount per Unit | 0.1mg per unit |
| Recommended Dose | titrate up from 2.5mg to 10mg (25 to 100 units) |
| Frequency | 1x per week |
| Injection Type | Subcutaneous |
| Timing | Same Day Every Week / Starting Dose Is 2.5 MG |
Dose Calculator
Based on 0.1mg per unit (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 10mg
Add BAC water: 1ml
Concentration: 0.1mg per unit
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.